Literature DB >> 2190141

Measles vaccines.

L E Markowitz1, W A Orenstein.   

Abstract

Measles vaccine is one of the safest and most effective vaccines currently available. Use of the vaccine has decreased the incidence of measles in both developed and developing countries. Nevertheless, preventable morbidity and mortality continue to occur. In the United States, the measles problem differs when it occurs among preschool-aged children or school-aged children. The former is a due to insufficient vaccine delivery. For measles in school-aged and college students, the problem is primarily vaccine failure, which should eventually be solved by a two-dose schedule. In developing countries, the major problem is vaccine delivery. Use of Edmonston-Zagreb measles vaccine in developing countries offers the promise of reducing disease rates in young infants; however, in both the United States and in developing countries, increasing immunization levels is essential.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2190141     DOI: 10.1016/s0031-3955(16)36907-3

Source DB:  PubMed          Journal:  Pediatr Clin North Am        ISSN: 0031-3955            Impact factor:   3.278


  11 in total

1.  C-reactive protein level in measles.

Authors:  Kyung-Yil Lee; Hyung-Shin Lee; Ja-Hyun Hong; Seung-Hoon Hahn; Jae-Kyun Hur; Jin-Han Kang
Journal:  Eur J Pediatr       Date:  2004-04-16       Impact factor: 3.183

2.  Antibody response to measles vaccination in Turkish children.

Authors:  N Kuyucu; U Dogru; N Akar
Journal:  Infection       Date:  1996 Mar-Apr       Impact factor: 3.553

3.  Elimination of measles in the Americas.

Authors:  J Furesz
Journal:  CMAJ       Date:  1996-11-15       Impact factor: 8.262

Review 4.  Two-dose measles vaccination schedules.

Authors:  S R Rosenthal; C J Clements
Journal:  Bull World Health Organ       Date:  1993       Impact factor: 9.408

5.  Measles outbreak in 31 schools: risk factors for vaccine failure and evaluation of a selective revaccination strategy.

Authors:  L Yuan
Journal:  CMAJ       Date:  1994-04-01       Impact factor: 8.262

6.  A study of maternally derived measles antibody in infants born to naturally infected and vaccinated women.

Authors:  R Brugha; M Ramsay; T Forsey; D Brown
Journal:  Epidemiol Infect       Date:  1996-12       Impact factor: 2.451

7.  A review of data needed to parameterize a dynamic model of measles in developing countries.

Authors:  Emily K Szusz; Louis P Garrison; Chris T Bauch
Journal:  BMC Res Notes       Date:  2010-03-16

8.  Underestimation of the incidence of measles in a population of French children.

Authors:  D Gendrel; M Chemillier-Truong; D Rodrique; J Raymond; O Bosco; P Saliou; P Lebon
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-12       Impact factor: 3.267

Review 9.  Measles control in the United States: problems of the past and challenges for the future.

Authors:  D L Wood; P A Brunell
Journal:  Clin Microbiol Rev       Date:  1995-04       Impact factor: 26.132

10.  Epitope dampening monotypic measles virus hemagglutinin glycoprotein results in resistance to cocktail of monoclonal antibodies.

Authors:  Patrycja J Lech; Gregory J Tobin; Ruth Bushnell; Emily Gutschenritter; Linh D Pham; Rebecca Nace; Els Verhoeyen; François-Loïc Cosset; Claude P Muller; Stephen J Russell; Peter L Nara
Journal:  PLoS One       Date:  2013-01-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.